3rd International Conference on Immunotherapy in Pediatric Oncology

October 1-2, 2012

Frankfurt/Main, Campus Niederrad, Lecture Hall 22
Theodor-Stern-Kai 7, 60590 Frankfurt
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>Welcome (Organizing Committee / Dean)</td>
</tr>
<tr>
<td>8:45 – 10:30</td>
<td><strong>Cellular Therapy 1: Antigen-specific and Gene Modified T-cells</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Michael Jensen, Peter Bader</td>
</tr>
<tr>
<td>8:45 – 9:05</td>
<td>Michel Sadelain, New York, USA</td>
</tr>
<tr>
<td></td>
<td>Modulating Potency of CAR-targeted T-cells</td>
</tr>
<tr>
<td>9:05 – 9:20</td>
<td>Winfried Wels, Frankfurt, Germany</td>
</tr>
<tr>
<td></td>
<td>Retargeting of Continuously Expanding NK cells for Adoptive Immunotherapy</td>
</tr>
<tr>
<td>9:20 – 9:40</td>
<td>Barbara Savoldo, Houston, USA</td>
</tr>
<tr>
<td></td>
<td>CD30 CAR study</td>
</tr>
<tr>
<td>9:40 – 10:00</td>
<td>Carl June, Philadelphia, USA</td>
</tr>
<tr>
<td></td>
<td>CD19 Chimeric Antigen receptor-modified T-cells in Leukemia</td>
</tr>
<tr>
<td>10:00 – 10:15</td>
<td>Stephen Grupp, Philadelphia, USA</td>
</tr>
<tr>
<td></td>
<td>Proliferation and Efficacy of Chimeric Antigen Receptor-armed T-cells (CART19) Correlates with a Cytokine Activation Syndrome (CAS) and Induction of Hemophagocytic Lymphohistiocytosis (HLH) that can be Managed by the IL-6 Antagonist Tocilizumab (toc)</td>
</tr>
<tr>
<td>10:15 – 10:30</td>
<td>Irene Pizzitola, Monza, Italy</td>
</tr>
<tr>
<td></td>
<td>Chimeric Antigen Receptor for Specific Targeting of Acute Myeloid Leukemia</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00 – 13:15</td>
<td><strong>Cellular Therapy 2: Targeting Pediatric Solid Tumors</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Barbara Savoldo, Michel Sadelain</td>
</tr>
<tr>
<td>11:00 – 11:20</td>
<td>Crystal Mackall, Bethesda, USA</td>
</tr>
<tr>
<td></td>
<td>Immunorestorative and Adoptive Cell Therapy for Pediatric Solid Tumors</td>
</tr>
<tr>
<td>11:20 – 11:40</td>
<td>Stephen Gottschalk, Houston, USA</td>
</tr>
<tr>
<td></td>
<td>Adoptive Immunotherapy for Osteosarcoma</td>
</tr>
<tr>
<td>11:40 – 11:55</td>
<td>Peter Bader, Frankfurt, Germany</td>
</tr>
<tr>
<td></td>
<td>Allogeneic SCT and Cell Therapy for RMS and Ewing Sarcoma</td>
</tr>
<tr>
<td>11:55 – 12:15</td>
<td>Michael Jensen, Seattle, USA</td>
</tr>
<tr>
<td></td>
<td>Genetically Engineered T-cells for Adoptive Therapy of Pediatric Cancer</td>
</tr>
<tr>
<td>12:15 – 12:30</td>
<td>Claudia Rossig, Muenster, Germany</td>
</tr>
<tr>
<td></td>
<td>Targeting G02 in Ewing Sarcoma</td>
</tr>
<tr>
<td>12:30 – 12:45</td>
<td>Matthias Woelfl, Wuerzburg, Germany</td>
</tr>
<tr>
<td></td>
<td>Differential Priming of Naïve T-cells: Implications for Adoptive Immunotherapy</td>
</tr>
<tr>
<td>12:45 – 13:00</td>
<td>Dean Lee, Houston, USA</td>
</tr>
<tr>
<td></td>
<td>NK Cells for Therapy of Neural Tumors</td>
</tr>
<tr>
<td>13:00 – 13:15</td>
<td>Antonio Pérez-Martinez, Madrid, Spain</td>
</tr>
<tr>
<td></td>
<td>Haplo-SCT and IL-15 Stimulated NK-Cell-Based Donor Lymphocyte Infusion Post-Transplantation as Treatment for Refractory Solid Tumors</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>14:15 – 15:30</td>
<td><strong>Hurdles and Barriers: Immunogenicity, Immune Escape and the Role of</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Tumor Microenvironment</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Claudia Rossig, Stephen Gottschalk</td>
</tr>
<tr>
<td>14:15 – 14:30</td>
<td>Simone Fulda, Frankfurt, Germany</td>
</tr>
<tr>
<td></td>
<td>Mechanisms of Cell Death</td>
</tr>
<tr>
<td>14:30 – 14:45</td>
<td>Vito Pistoia, Genoa, Italy</td>
</tr>
<tr>
<td></td>
<td>Immunosuppressive Microenvironment in Neuroblastoma</td>
</tr>
<tr>
<td>14:45 – 15:00</td>
<td>Ulrike Koehl, Hannover, Germany</td>
</tr>
<tr>
<td></td>
<td>NK Cells and Tumor Immune Escape</td>
</tr>
<tr>
<td>15:00 – 15:15</td>
<td>Michiel Kroesen, Nijmegen, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>Analysis of the Immunobiology of the TH-MYCN Transgenic Mouse Model</td>
</tr>
<tr>
<td></td>
<td>Reveals Low Immunogenicity and Suggests a Role for NK Cells</td>
</tr>
<tr>
<td></td>
<td>in the Anti-Neuroblastoma Response</td>
</tr>
<tr>
<td>15:15 – 15:30</td>
<td>Christian Capitini, Madison, USA</td>
</tr>
<tr>
<td></td>
<td>Optimizing 19F-MRI for Monitoring of Adoptive Cellular Therapies in</td>
</tr>
<tr>
<td></td>
<td>vivo</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16:00 – 17:10</td>
<td><strong>Vaccine Strategies and Antigen Presentation</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Catherine Bollard, Winfried Wels</td>
</tr>
<tr>
<td>16:00 – 16:15</td>
<td>Hans Stauss, London, UK</td>
</tr>
<tr>
<td></td>
<td>WT-1 Specific T-cell Therapy</td>
</tr>
<tr>
<td>16:15 – 16:35</td>
<td>John Barrett, Bethesda, USA</td>
</tr>
<tr>
<td></td>
<td>Immunotherapy for Hematological Malignancies: Vaccines or T-cells?</td>
</tr>
<tr>
<td>16:35 – 16:55</td>
<td>Richard O’Reilly, New York, USA</td>
</tr>
<tr>
<td></td>
<td>Allogeneic Donor-Derived WT-1 Specific T-cells for Adoptive Therapy</td>
</tr>
<tr>
<td></td>
<td>of Leukemia and Solid Tumors</td>
</tr>
<tr>
<td>16:55 – 17:10</td>
<td>Rimas Orentas, Bethesda, USA</td>
</tr>
<tr>
<td></td>
<td>Modeling the Immune Landscape of Pediatric Cancers: Bioinformatic</td>
</tr>
<tr>
<td></td>
<td>Identification of Targets for CAR- and Antibody-Based Therapy</td>
</tr>
<tr>
<td>17:10 – 19:00</td>
<td>Poster Session</td>
</tr>
<tr>
<td>20:00</td>
<td>Dinner at the InterContinental Frankfurt</td>
</tr>
<tr>
<td></td>
<td>Wilhelm-Leuschner-Str. 43, 60329 Frankfurt</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>8:30 – 10:10</td>
<td>Haploidentical Transplantation and Innate Immunity</td>
</tr>
<tr>
<td>8:30 – 8:45</td>
<td></td>
</tr>
<tr>
<td>8:45 – 9:05</td>
<td></td>
</tr>
<tr>
<td>9:05 – 9:20</td>
<td></td>
</tr>
<tr>
<td>9:20 – 9:40</td>
<td></td>
</tr>
<tr>
<td>9:40 – 9:55</td>
<td></td>
</tr>
<tr>
<td>9:55 – 10:10</td>
<td>Abstract 7</td>
</tr>
<tr>
<td>10:10 – 10:40</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:40 – 13:05</td>
<td>Immune Cells in Allogeneic Transplantation</td>
</tr>
<tr>
<td>10:40 – 11:00</td>
<td></td>
</tr>
<tr>
<td>11:00 – 11:20</td>
<td></td>
</tr>
<tr>
<td>11:20 – 11:35</td>
<td></td>
</tr>
<tr>
<td>11:35 – 11:50</td>
<td></td>
</tr>
<tr>
<td>11:50 – 12:05</td>
<td></td>
</tr>
<tr>
<td>12:05 – 12:20</td>
<td></td>
</tr>
<tr>
<td>12:35 – 12:50</td>
<td></td>
</tr>
<tr>
<td>12:50 – 13:05</td>
<td>Abstract 2</td>
</tr>
<tr>
<td>13:05 – 14:05</td>
<td>Lunch</td>
</tr>
<tr>
<td>Time</td>
<td>Title</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>14:05 – 16:20</td>
<td>Antibody/Imunoconjugate Approaches</td>
</tr>
<tr>
<td></td>
<td>Chairs: Katharine Hsu, Paul-Gerhard Schlegel</td>
</tr>
<tr>
<td>14:05 – 14:20</td>
<td>Max Topp, Wuerzburg, Germany</td>
</tr>
<tr>
<td>14:20 – 14:40</td>
<td>Paul Sondel, Madison, USA</td>
</tr>
<tr>
<td>14:40 – 15:00</td>
<td>Alan Wayne, Bethesda, USA</td>
</tr>
<tr>
<td>15:00 – 15:20</td>
<td>Anna Franklin, Houston, USA</td>
</tr>
<tr>
<td>15:20 – 15:35</td>
<td>Christine Mauz-Koerholz, Halle, Germany</td>
</tr>
<tr>
<td>15:35 – 15:50</td>
<td>Birgit Burkhardt, Muenster, Germany</td>
</tr>
<tr>
<td>15:50 – 16:05</td>
<td>Peter Lang, Tuebingen, Germany</td>
</tr>
<tr>
<td>16:05 – 16:20</td>
<td>Nikolai Siebert, Greifswald, Germany</td>
</tr>
<tr>
<td>16:20 – 16:35</td>
<td>Concluding Remarks</td>
</tr>
</tbody>
</table>

Kindly supported by:

Kind-Philipp-Stiftung für Leukämieforschung

Adolf Messer Stiftung

CGT Frankfurt
Poster Session (Day 1, Oct. 1, 2012, 17:10 – 19:00)


[16] Polyfunctional CD4+ and CD8+ T-cells against NY-ESO-1 for induction of THelper1-driven immune responses in vivo by adoptive T cell transfer. S. Kayser*, C. Boß, M. Schumm, V. Icheva, St. Stevanovi, P. Lang, R. Handgretinger, T. Feuchttinger, Tuebingen, Germany


*Presenting author

[20] Reduced risk of relapse in pediatric ALL after haploidentical transplantation of T-cell depleted grafts from KIR haplotype B donors. L. Oevermann, S. Michaelis*, M. Mezger, M. Pfeiffer, P. Lang, T. Feuchtinger, J. Toporski, F. Locatelli, R. Handgretinger, Tuebingen, Germany


[22] GMP-grade generation of multivirus-specific T-cells for adoptive T-cell immunotherapy. L. Joachim*, T. Feuchtinger, Tuebingen, Germany


[25] Increased GD2 expression of drug resistant neuroblastoma cell lines facilitates GD2-specific killing by genetically engineered NK cells. D. Seidel*, A. Shibina, CP Reynolds, WS Wels, N. Huebener,HN Lode, Greifwald, Germany


[34] A Novel Model of Immune Equilibrium and Minimal Residual Disease (MRD) in Acute Lymphoblastic Leukemia (ALL). AE Seif*, DM Barrett, SA Grupp, GSD Reid, Philadelphia, USA

*Presenting author

[37] NK cell subsets with high antileukemic activity identified by CD107a assay. P. Schlegel*, P. Lang, K. Witte, R. Teltschik, R. Handgretinger, A. Horrer, M. Pfeiffer, Tuebingen, Germany

[38] Evaluation of the Pediatric Preclinical Testing Program (PPTP) in vitro cell line panel as targets of NK cell cytotoxicity. AK Ray, SS Somanchi, ZE Cobanoglu, B. Geier, DA Lee*, Houston, Texas

[40] NK cell therapy and aerosol IL-2 for the treatment of osteosarcoma lung metastasis. SR Guma, DA Lee*, ES Kleinerman, Houston, Texas

[42] Engineering natural killer cells through trogocytosis for adoptive immunotherapy. SS Somanchi, A. Somanchi, LJN Cooper, DA Lee*, Houston, Texas

[43] High-dimension phenotyping to determine the potential susceptibility of juvenile myelomonocytic leukemia to NK cell immunotherapy. S. Martinez, VV Senyukov, YL Liu, PD Emanuel, DA Lee*, Houston, Texas

[44] Chemokine receptor expression, migration, and survival of NK cells expanded with mblL-15 or mblL-21. M. Aliru, A. Wan, SS Somanchi, CJ Denman, DA Lee*, Houston, Texas

[45] IL-27 initiates strong, early NK cell-mediated effector functions in a murine model. MS Thakar*, P. Kumar, K. Rajasekaran, K. Schuld, S. Malarkannan, Wisconsin, USA

[47] Enhancing anti-CD22 chimeric antigen Receptor (CAR) activity by altering the target antigen binding site. W. Haso*, DW Lee, IH Pastan, DS Dimitrov, CL Mackall, RJ Orentas, Bethesda, USA

[48] Transgenic allorestricted T-cells against Ewing Tumors. U. Thiel*, G. Richter, F. Blaescheke, HJ Kolb, St. Burdach, Muenchen, Germany


*Presenting author